Neurostar RTMS denied as duplicate or overlapping therapy by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for neurostar rtms are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UHC Denied NeuroStar TMS as Duplicate Therapy — and How to Appeal

NeuroStar is an FDA-cleared transcranial magnetic stimulation (TMS) system used to treat major depressive disorder (MDD) in adults, and in some cases obsessive-compulsive disorder. A "duplicate therapy" denial from UnitedHealthcare typically means the system identified that you are currently receiving, or recently received, another treatment it considers therapeutically equivalent — most often electroconvulsive therapy (ECT) or a course of TMS from a different device — and has determined that concurrent or sequential coverage is not warranted.

### Why This Denial Is Appealable

TMS and other brain stimulation modalities are not clinically interchangeable in all patients. TMS and ECT differ substantially in their mechanism, side-effect profile, administration setting, anesthesia requirements, and patient populations for whom they are appropriate. If your prescribing psychiatrist has determined that TMS is clinically distinct from whatever treatment UHC characterized as the "duplicate," that clinical judgment must be considered in a full-and-fair review. UHC is required under ACA Section 2719 and, for ERISA plans, Section 503, to evaluate the clinical basis of the denial — not simply apply an administrative rule.

### Your Appeal Timeline

• Internal appeal: File within the timeframe on your denial letter. UHC must decide pre-service internal appeals within 30 days and post-service within 60 days.
• External review: If the internal appeal fails, you generally have four months from that denial to request independent external review. The reviewer's decision is binding.
• Expedited option: If standard timing would seriously jeopardize your health, request expedited review; decisions are required within 72 hours.

### Documentation to Gather

1. Diagnosis confirmation — psychiatric evaluation notes documenting your diagnosis (MDD, OCD, or other approved indication) and current symptom severity using a validated scale. 2. Prior-treatment history — a chronological list of all antidepressant or other treatments tried, including the therapy UHC identified as the "duplicate," with start/stop dates and clinical outcomes. 3. Clinical distinction letter — a letter from your psychiatrist explaining precisely why TMS is not duplicative of the other treatment, including any differences in target symptom, side-effect tolerability, or clinical appropriateness. 4. Chart entries — progress notes showing how your condition has responded (or not responded) to the treatment UHC considers equivalent.

### Criteria-Mapping Structure

Request UHC's published coverage policy for TMS and for the therapy it identified as the duplicate. For each requirement or exclusion criterion in UHC's policy, write the requirement verbatim and then provide the chart-based fact that addresses it. The goal is to show, point by point, that your clinical situation falls outside the duplicate-therapy exclusion. Attach the applicable psychiatric society guideline (e.g., from the relevant APA or AHRQ guidance) that supports TMS as a clinically distinct treatment option for your specific presentation.